Orion Corporation

Orion Corporation (Finnish: Orion Oyj),[2][3] founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.[4]

This article is about the pharmaceutical company. For other companies named Orion, see Orion (disambiguation).

Orion Corporation
Native name
Orion Oyj
TypeJulkinen osakeyhtiö
Nasdaq Helsinki: ORNAV,ORNBV
IndustryPharmaceutical industry
Founded21 September 1917 (1917-09-21)
HeadquartersEspoo, Finland
Key people
Timo Lappalainen (President and CEO), Mikael Silvennoinen (Chairman)
ProductsPharmaceuticals and active pharmaceutical ingredients
Revenue €1.078 billion (2020)
€280.1 million (2020)
€219.9 million (2020)
Total assets €1.115 billion (2020)
Total equity €731.3 million (2020)
Number of employees
 3,337 (2020)
Websitewww.orion.fi/en
Footnotes / references
[1]

Orion's class A and B shares are listed on the Helsinki Stock Exchange.

Notable products

The following are Orion's top-selling product lines as of March 2021.[5]

Trade name Indication
Stalevo, Comtess, Comtan Parkinson's disease
Easyhaler asthma, COPD
Simdax acute heart failure
dexdor intensive care sedative
Dexdomitor, Domitor, Domosedan, Antisedan animal sedatives
Nubeqa non-metastatic castration-resistant prostate cancer
Solomet inflammation
Divina series menopausal symptoms
Burana inflammatory pain
Marevan anticoagulant

References
  1. https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2020/en_orion_fy_2020.pdf
  2. "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
  3. "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.
  4. "About Orion".
  5. https://www.orion.fi/globalassets/documents/orion-group/investors/interim-reports/2021/en_orion_q1_2021_slides.pdf
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.